Superdiluted atropine at 0.01% reduces progression in children and adolescents. A 5 year study of safety and effectiveness
- PMID: 29398233
- DOI: 10.1016/j.oftal.2017.12.015
Superdiluted atropine at 0.01% reduces progression in children and adolescents. A 5 year study of safety and effectiveness
Abstract
Objective: To confirm the clinical security and effectiveness of the daily application of 0.01% superdiluted atropine eyedrops in the progression of myopia in children.
Material and methods: A total of 200 children 9-12 years of age were randomised into a treated group and a control without treatment. Refraction under cycloplegia was performed.
Results: Myopia progression of the treated group was -0.14±0.35 versus -0.65±0.54 in the control group without treatment. Only 2% of patients were forced to stop treatment due to side effects.
Conclusion: Atropine superdiluted atropine 0.01% eyedrops is effective and well tolerated, and reduced myopia progression by 25%.
Keywords: 0,01%; 0.01%; Children; Frenar; Miopía; Myopia; Niños; Progresión; Progression; Slow-down.
Copyright © 2018 Sociedad Española de Oftalmología. Publicado por Elsevier España, S.L.U. All rights reserved.
Comment in
-
Superdiluted atropine at 0.01% reduces myopia progression in children and adolescents. A 5-year study of safety and effectiveness.Arch Soc Esp Oftalmol (Engl Ed). 2019 Mar;94(3):e19. doi: 10.1016/j.oftal.2018.08.007. Epub 2018 Oct 29. Arch Soc Esp Oftalmol (Engl Ed). 2019. PMID: 30385080 English, Spanish. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources